 recombin alpha interferon metastat renal cell carcinoma cooper phase II studi total evalu patient advanc renal cell carcinoma IU squar meter bodi surfac recombin alpha interferon time week cooper phase II studi toxic death termin renal failur patient toxic present case overal respons rate month treatment partial respons minor respons complet respons fifteen month long-last stabil diseas percent